Clinical Trials Browser

INDUSTRY × Interventional × talimogene laherparepvec × Clear all

NCT04068181 2025-01-07

Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).

Phase 2 Completed

72 enrolled 28 charts

Melanoma

NCT02509507 2024-08-06

MASTERKEY-318

Phase 1/2 Completed

127 enrolled 37 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT01740297 2024-05-14

Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma

Phase 1/2 Completed

217 enrolled 27 charts

Melanoma

NCT03256344 2024-05-14

Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

Phase 1 Completed

36 enrolled 16 charts

BreastGastrointestinal

Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT02756845 2024-02-20

Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors

Phase 1 Completed

15 enrolled 13 charts

Advanced Non CNS Tumors

NCT02890368 2023-04-05

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

Phase 1 Terminated

BreastDermatologicLymphoidSarcoma

Breast Neoplasms, Carcinoma, Squamous Cell, Melanoma, Mycosis Fungoides, Sarcoma, Carcinoma, Merkel Cell

NCT02263508 2022-11-14

MASTERKEY-265

Phase 3 Terminated

713 enrolled 34 charts

Melanoma

NCT02288897 2022-01-19

PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

Phase 3 Terminated

20 enrolled 13 charts

Melanoma, Recurrence

NCT02366195 2021-11-30

TVEC-325

Phase 2 Completed

112 enrolled 22 charts

Melanoma

NCT02626000 2021-09-08

MASTERKEY232

Phase 1 Completed

36 enrolled 18 charts

Squamous Cell Carcinoma of Head and Neck

NCT02014441 2019-11-20

Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec

Phase 2 Completed

61 enrolled 27 charts

Melanoma

NCT00769704 2016-07-13

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

Phase 3 Completed

437 enrolled 19 charts

Melanoma

NCT00402025 2016-04-15

Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer

Phase 1 Completed

17 enrolled 14 charts

Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Pancreatic Neoplasms

NCT01161498 2016-02-08

Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer

Phase 3 Terminated

5 enrolled 8 charts

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00289016 2015-12-18

A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma

Phase 2 Completed

50 enrolled 14 charts

Melanoma

NCT01368276 2015-12-18

An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma

Phase 3 Completed

31 enrolled 11 charts

Melanoma

NCT02574260 2015-12-17

An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)

Phase 2 Completed

3 enrolled 8 charts

Melanoma